# DTG Resistance Emerging Beyond Clinical Trial Levels

**ID:** RES-007
**Year:** 2024
**Source:** WHO
**Link:** [https://www.who.int/publications-detail-redirect/9789240086319](https://www.who.int/publications-detail-redirect/9789240086319)

---

## Abstract

WHO analysis showing dolutegravir resistance emerging at 3.9-19.6% in real-world settings, exceeding clinical trial observations.

---

## Key Concepts

- Primary research focus from 2023-2025 HIV literature
- Relevant to understanding HIV biology, treatment, or prevention
- Contributes to the broader HIV research landscape

---

## Relevance to Project

This paper contributes to the Ternary VAE bioinformatics project by providing context on:
- HIV sequence evolution and variability
- Biological constraints on viral fitness
- Therapeutic targets and resistance mechanisms

---

*Added: 2025-12-24*
